Phase 3 clinical trial of ambroxol for Parkinson's confirmed
Cure Parkinson’s is pleased to announce that a large-scale phase 3 clinical trial of ambroxol, to determine whether the drug can slow the progression of Parkinson’s.
Learn more
The AND-PD Trial
This study (ANxiety with or without depressive features in Parkinson’s Disease ‘AND-PD’) is an observational and imaging study where people at different stages of Parkinson’s will be assessed and followed for one year. This study, led by Professor Anette Schrag, is looking to recruit around…
The Bydureon (exenatide) phase 3 trial
Cure Parkinson’s is delighted to be supporting two sub-studies within the Bydureon (exenatide) phase 3 trial which is recruiting from six sites in the UK. This phase 3 clinical trial is testing the efficacy of exenatide in a large cohort of people with Parkinson’s and…
The AIM-PD trial (ambroxol)
Supported and funded by Cure Parkinson’s, Van Andel Institute and the John Black Foundation, the next phase of this trial programme will follow shortly. Phase 2 of the ‘AIM-PD’ study was a proof of concept study and involved 17 people with the genetic form of Parkinson’s over…
The UP-Study trial (UDCA)
This trial is now complete. Supported by Cure Parkinson’s and the J P Moulton Foundation, the results are expected in 2021. Originally used to treat cirrhosis of the liver, researchers found that the rescue effect of UDCA on the liver cells may actually be due…
The PD-STAT/Simvastatin study results
Why is this important? In 2012, an international committee of Parkinson’s experts brought together by Cure Parkinson’s prioritised simvastatin for clinical evaluation in Parkinson’s. The International Linked Clinical Trials (iLCT) committee believed that there was considerable supporting evidence indicating that this widely used medication may…